Rebecca Soares, MD
Retina Specialist · Springfield, MANPI 1811346414
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,750 of the $9,663 with a category attached, or 69.9%. AbbVie accounts for 84.5% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2024 at $8,245 and has fallen 91.3% since, to $720 in 2025.
Across 43 payments — averaging $224.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$8K
- Alcon$441
- Genentech USA, Inc.$283
- Glaukos Corporation$238
- Regeneron Healthcare Solutions, Inc.$236
- Astellas Pharma US Inc$75
- plus $222 from 6 others
What the payments were for
- Consulting fees$6,75070%
- Travel & lodging$8629%
- Food & beverage$1,71418%
- Other$3373%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 17 | $8,168 |
| Alcon | 2 | $441 |
| Genentech USA, Inc. | 7 | $283 |
| Glaukos Corporation | 2 | $238 |
| Regeneron Healthcare Solutions, Inc. | 5 | $236 |
| Astellas Pharma US Inc | 3 | $75 |
| Alimera Sciences, Inc. | 1 | $75 |
| Amgen | 2 | $45 |
| Neurotech Pharmaceuticals, Inc. | 1 | $34 |
| Harrow Eye, LLC | 1 | $32 |
| Apellis Pharmaceuticals, Inc. | 1 | $19 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OZURDEX$7,712
- Unity$337
- iStent inject Trabecular Micro-Bypass Stent System$238
- VABYSMO$122
- EYLEA$104
How this compares
$9,663 in reported general payments places this provider in the 80th percentile of 26 retina specialist providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 205 | $8,351 |
| Ofloxacin | 96 | $1,475 |
| Ketorolac Tromethamine | 46 | $999 |
| Brimonidine Tartrate | 24 | $870 |
| Atropine Sulfate | 11 | $405 |
| Latanoprost | 18 | $302 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 22 | $225 |
| ErythromycinErythromycin Base | 14 | $162 |
| Timolol Maleate | 17 | $127 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Springfield
- Jeffrey HeierBoston$1.5M
- Alyse RichardDartmouth$37K
- Andre WitkinBoston$23K
- Chirag ShahBoston$14K
- Elite Bor-ShavitLancaster$11K
- Brian BalliosBoston$3K
- Brad BakerWorcester$2K
- David ReedPlymouth$2K
- Ilya LeskovBoston$2K
- Bryan HongWorcester$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.